Three days after a terrific presentation from @hripcsa, @David_Madigan, @msuchard and Rita Kukafka about OHDSI’s work with the FDA Best program around monitoring the safety and effectiveness of COVID-19 vaccines, the first study from this work was posted to the MedRxiv preprint server.
Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study
Congratulations to @xintongli, @Daniel_Prieto and the full team on this important study. Dani posted a recent twitter thread that highlighted the background and some findings from the study.
If you missed any of Tuesday’s community call presentation about our work with the FDA Best program, it is available below.